Sutro Biopharma(NASDAQ) STRO

Sutro Biopharma develops new medicines for cancer and immune diseases. Its therapies aim to help patients with limited treatment options. The company partners with larger drugmakers to advance its research.

What’s Cooking in Sutro’s Lab?

• Antibody-Drug Conjugates (ADCs): Engineered proteins that deliver targeted cancer treatment; the company's revenue is principally generated from related collaborations.
• Bispecific ADCs: Proteins designed to bind two targets at once, aiming for more precise cancer therapy.
• Immunostimulatory ADCs: Treatments that combine targeted delivery with immune system activation, focused on hard-to-treat cancers.
• Dual-Payload ADCs: Molecules carrying two cancer-fighting agents, intended for solid tumors in early research stages.
• Collaboration Services: Research and development work for partners like Astellas and Ipsen, representing nearly all 2025 revenue.

Growth Spurts and Strategic Moves

• Launched Phase 1 trial for STRO-004 in November 2025, expanding clinical pipeline.
• Entered and expanded partnerships with Astellas, Merck, BMS, EMD Serono, and Vaxcyte since 2023.
• Transitioned to external manufacturing by transferring technology to contract manufacturers in 2025.
• Restructured operations in March and September 2025, reducing workforce by about two-thirds.
• Deprioritized late-stage clinical program STRO-002 in March 2025 to focus on earlier-stage assets.

Why Sutro Stands Out (Without the Lab Coat)

Sutro’s cell-free protein technology allows rapid, precise drug development without using living cells. Its platform can create and test thousands of protein variants in a day, speeding up research. The company’s intellectual property portfolio and external manufacturing model support flexibility and scalability.

Five Things You Need to Know

• Revenue was $102.5 million in 2025, up 65% from 2024.
• Net loss was $191.1 million in 2025, improved from $227.5 million in 2024.
• Collaboration with Astellas and Ipsen made up 99.3% of 2025 revenue.
• Cash, cash equivalents, and securities were $141.4 million as of December 31, 2025.
• Employee count dropped to 137 by end of 2025, down from 269 previously.

Bottom Line

Sutro has shifted from internal manufacturing to a leaner, partnership-driven model. The company remains focused on early-stage drug development and external collaborations.